文献速递认知障碍与痴呆

基于生物标志物的轻度认知障碍预后模型(ABIDE研究)

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
PubMed 文献 · Lancet Neurol · 2019-09-13

该建模研究纳入欧洲和北美四个队列共2611例轻度认知障碍(MCI)患者,评估并更新了基于人口学、海马体积和脑脊液生物标志物的风险预测模型。

要点

  • 验证的人口学模型、海马体积模型和更新的脑脊液生物标志物模型预后性能 adequate 且校准良好。
  • 这些模型有助于临床解读MCI患者的脑脊液生物标志物和海马体积结果。

核心结论

  • 生成的跨队列稳健风险模型增加了潜在临床适用性,可辅助临床解读MCI患者的脑脊液生物标志物和海马体积结果。

研究设计与样本

  • 建模研究,纳入欧洲和北美四个队列(EMIF-AD n=883、ADNI n=829、ADC n=666、BioFINDER n=233)共2611例MCI患者。

主要发现

  • 1007例(39%)进展为痴呆。

关键数值与推荐

  • 纳入标准为基线诊断MCI、至少6个月随访、有基线MMSE和MRI或脑脊液生物标志物评估。
  • 主要终点为临床进展为任何类型痴呆。
  • 使用Harrell's C统计量评估预后性能,并通过比较观察与预期生存评估模型校准。

临床怎么用

  • 模型可帮助临床医生解读MCI患者的脑脊液生物标志物和海马体积结果。
  • 模型有助于研究和临床环境为阿尔茨海默病精准医学做准备。

局限性

  • 未来研究应关注模型的临床效用,特别是其使用是否影响参与者的理解、情绪健康和行為。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. METHODS: In this modelling study, we included people with mild cognitive impairment (MCI) from single-centre and multicentre cohorts in Europe and North America: the European Medical Information Framework for Alzheimer's Disease (EMIF-AD; n=883), Alzheimer's Disease Neuroimaging Initiative (ADNI; n=829), Amsterdam Dementia Cohort (ADC; n=666), and the Swedish BioFINDER study (n=233). Inclusion criteria were a baseline diagnosis of MCI, at least 6 months of follow-up, and availability of a baseline Mini-Mental State Examination (MMSE) and MRI or CSF biomarker assessment. The primary endpoint was clinical progression to any type of dementia. We evaluated performance of previously developed risk prediction models-a demographics model, a hippocampal volume model, and a CSF biomarkers model-by evaluating them across cohorts, incorporating different biomarker measurement methods, and determining prognostic performance with Harrell's C statistic. We then updated the models by re-estimating parameters with and without centre-specific effects and evaluated model calibration by comparing observed and expected survival. Finally, we constructed a model combining markers for amyloid deposition, tauopathy, and neurodegeneration (ATN), in accordance with the National Institute on Aging and Alzheimer's Association research framework. FINDINGS: We included all 2611 individuals with MCI in the four cohorts, 1007 (39%) of whom progressed to dementia. The validated demographics model (Harrell's C 0·62, 95% CI 0·59-0·65), validated hippocampal volume model (0·67, 0·62-0·72), and updated CSF biomarkers model (0·72, 0·68-0·74) had adequate prognostic performance across cohorts and were well calibrated. The newly constructed ATN model had the highest performance (0·74, 0·71-0·76). INTERPRETATION: We generated risk models that are robust across cohorts, which adds to their potential clinical applicability. The models could aid clinicians in the interpretation of CSF biomarker and hippocampal volume results in individuals with MCI, and help research and clinical settings to prepare for a future of precision medicine in Alzheimer's disease. Future research should focus on the clinical utility of the models, particularly if their use affects participants' understanding, emotional wellbeing, and behaviour. FUNDING: ZonMW-Memorabel.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. van Maurik IS, Vos SJ, Bos I, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019. PMID: 31526625. doi:10.1016/S1474-4422(19)30283-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。